医学
阿替唑单抗
泌尿系统
肿瘤科
泌尿科
内科学
癌症
免疫疗法
无容量
作者
Cora N. Sternberg,Yohann Loriot,Xavier Garcia Del Muro,Friedemann Zengerling,Friedemann Zengerling,Cora N Sternberg,Friedemann Zengerling,Friedemann Zengerling,Xavier Garcia Del Muro,Cora N Sternberg,Aristotelis Bamias,Xavier Garcia Del Muro,Xavier Garcia Del Muro,Thomas Powles,Cora N Sternberg,Marija Gamulin,Lajos Géczi,Cora N Sternberg,Friedemann Zengerling,Xavier Garcia Del Muro,Pari Skamnioti,Friedemann Zengerling
标识
DOI:10.1016/j.euf.2024.05.007
摘要
We assessed the safety of atezolizumab in unselected patients (including understudied populations typically excluded from clinical trials) with pretreated urinary tract carcinoma (UTC). The prespecified final analysis updates previously reported safety and efficacy data.
科研通智能强力驱动
Strongly Powered by AbleSci AI